for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akero Therapeutics Inc

AKRO.OQ

Latest Trade

20.94USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

17.84

 - 

34.78

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.94
Open
--
Volume
--
3M AVG Volume
3.87
Today's High
--
Today's Low
--
52 Week High
34.78
52 Week Low
17.84
Shares Out (MIL)
34.86
Market Cap (MIL)
747.79
Forward P/E
-6.90
Dividend (Yield %)
--

Next Event

Q3 2021 Akero Therapeutics Inc Earnings Release

Latest Developments

More

Akero Therapeutics Receives FDA Fast Track Designation For NASH Treatment

Akero Therapeutics Reports Second Quarter 2021 Financial Results

Akero Therapeutics Reports Q4 And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akero Therapeutics Inc

Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. The Company's lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, which targets the inflammation and fibrosis of the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).

Industry

Biotechnology & Drugs

Contact Info

601 Gateway Boulevard, Suite 350

SOUTH SAN FRANCISCO, CA

94080

United States

+1.650.4876488

https://www.akerotx.com/

Executive Leadership

Mark T. Iwicki

Independent Non-Executive Chairman of the Board

Andrew Cheng

President, Chief Executive Officer, Director

Jonathan Young

Co-Founder, Chief Operating Officer, Executive Vice President, Secretary

Timothy Rolph

Co-Founder, Chief Scientific Officer

William White

Chief Financial Officer, Executive Vice President and Head of Corporate Development and Treasurer

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-2.900

2020

-2.520

2021(E)

-3.108
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-58.51
Return on Equity (TTM)
-54.04

Latest News

Latest News

BRIEF-Akero Therapeutics Reports Q4 Loss Per Share $0.55

* AKERO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up